IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Inclusion Criteria:

• Patients ≥ 18 years old

• Patients must have a specific pathologically confirmed and documented advancedand/or metastatic solid tumor indication

• Patients must have received or not be eligible for all available indicatedstandard-of-care treatments

• Measurable disease according to RECIST 1.1

• Confirmed HLA status

• ECOG Performance Status of 0 to 1

• Adequate baseline hematologic, hepatic and renal function, acceptable coagulationstatus

Exclusion Criteria:

• Other active malignancies that require treatment or that might interfere with thetrial endpoints (ongoing adjuvant anti-hormonal treatment is allowed)

• The patient is pregnant or is breastfeeding

• History of hypersensitivity to components of IMA402 or rescue medications, if noalternative treatment option is available

• The patient has concurrent severe and/or uncontrolled medical disease. Any otherhealth condition that would, in the investigator's judgement, contraindicate thepatient's participation in the clinical trial because of safety concerns orcompliance with clinical trial procedures

• Patients with active brain metastases